The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Javitt, D. C.
* Articles by Lindenmayer, J. P.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Javitt, D. C.
* Articles by Lindenmayer, J. P.

Am J Psychiatry 1994; 151:1234-1236
Copyright © 1994 by American Psychiatric Association

BRIEF REPORTS

Amelioration of negative symptoms in schizophrenia by glycine

DC Javitt, I Zylberman, SR Zukin, U Heresco-Levy and JP Lindenmayer
Department of Psychiatry, Albert Einstein College of Medicine, Bronx Psychiatric Center, NY 10461.

Phencyclidine induces a psychotomimetic state by blocking neurotransmission at N-methyl-D-aspartic acid (NMDA) receptors. In a double-blind, placebo-controlled fashion, 14 medicated patients with chronic schizophrenia were treated with glycine, a potentiator of NMDA- receptor-mediated neurotransmission. Significant improvement in negative symptoms occurred in the group given glycine but not in the group given placebo, suggesting that potentiation of NMDA-receptor- mediated neurotransmission may represent an effective treatment for neuroleptic-resistant negative symptoms in schizophrenia.


This article has been cited by other articles:


Home page
 Am. J. PsychiatryHome page
R. W. Buchanan, D. C. Javitt, S. R. Marder, N. R. Schooler, J. M. Gold, R. P. McMahon, U. Heresco-Levy, and W. T. Carpenter
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments
Am J Psychiatry, October 1, 2007; 164(10): 1593 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman
Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia
Schizophr Bull, September 1, 2007; 33(5): 1120 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
P. D. Butler, V. Zemon, I. Schechter, A. M. Saperstein, M. J. Hoptman, K. O. Lim, N. Revheim, G. Silipo, and D. C. Javitt
Early-Stage Visual Processing and Cortical Amplification Deficits in Schizophrenia
Arch Gen Psychiatry, May 1, 2005; 62(5): 495 - 504.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
G. G. Kinney, C. Sur, M. Burno, P. J. Mallorga, J. B. Williams, D. J. Figueroa, M. Wittmann, W. Lemaire, and P. J. Conn
The Glycine Transporter Type 1 Inhibitor N-[3-(4'-Fluorophenyl)-3-(4'-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior
J. Neurosci., August 20, 2003; 23(20): 7586 - 7591.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. G. Kinney, M. Burno, U. C. Campbell, L. M. Hernandez, D. Rodriguez, L. J. Bristow, and P. J. Conn
Metabotropic Glutamate Subtype 5 Receptors Modulate Locomotor Activity and Sensorimotor Gating in Rodents
J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 116 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
S. M. Clinton, V. Haroutunian, K. L. Davis, and J. H. Meador-Woodruff
Altered Transcript Expression of NMDA Receptor-Associated Postsynaptic Proteins in the Thalamus of Subjects With Schizophrenia
Am J Psychiatry, June 1, 2003; 160(6): 1100 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
L. Chen, M. Muhlhauser, and C. R. Yang
Glycine Tranporter-1 Blockade Potentiates NMDA-Mediated Responses in Rat Prefrontal Cortical Neurons In Vitro and In Vivo
J Neurophysiol, February 1, 2003; 89(2): 691 - 703.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
D. L. Walker, K. J. Ressler, K.-T. Lu, and M. Davis
Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of D-Cycloserine as Assessed with Fear-Potentiated Startle in Rats
J. Neurosci., March 15, 2002; 22(6): 2343 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Andiné, N. Widermark, R. Axelsson, G. Nyberg, U. Olofsson, E. Mårtensson, and M. Sandberg
Characterization of MK-801-Induced Behavior as a Putative Rat Model of Psychosis
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1393 - 1408.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. A. Johnson, N. T. Luu, T. A. Herbst, R. Knapp, D. Lutz, A. Arai, G. A. Rogers, and G. Lynch
Synergistic Interactions between Ampakines and Antipsychotic Drugs
J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 392 - 397.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
W. T. Carpenter Jr., R. W. Buchanan, B. Kirkpatrick, and A. F. Breier
Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia
Am J Psychiatry, February 1, 1999; 156(2): 299 - 303.
[Abstract] [Full Text]

Home page
 Am. J. PsychiatryHome page
S. G. Potkin, Y. Jin, B. G. Bunney, J. Costa, and B. Gulasekaram
Effect of Clozapine and Adjunctive High-Dose Glycine in Treatment-Resistant Schizophrenia
Am J Psychiatry, January 1, 1999; 156(1): 145 - 147.
[Abstract] [Full Text]

Home page
 Arch Gen PsychiatryHome page
N. B. Farber, J. W. Newcomer, and J. W. Olney
Glycine Agonists: What Can They Teach Us About Schizophrenia?
Arch Gen Psychiatry, January 1, 1999; 56(1): 13 - 17.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
D. C. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, D. A. Schoenfeld, D. L. Hayden, R. McCarley, and J. T. Coyle
A Placebo-Controlled Trial of D-Cycloserine Added to Conventional Neuroleptics in Patients With Schizophrenia
Arch Gen Psychiatry, January 1, 1999; 56(1): 21 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
U. Heresco-Levy, D. C. Javitt, M. Ermilov, C. Mordel, G. Silipo, and M. Lichtenstein
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Arch Gen Psychiatry, January 1, 1999; 56(1): 29 - 36.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Bergeron, T. M. Meyer, J. T. Coyle, and R. W. Greene
Modulation of N-methyl-D-aspartate receptor function by glycine transport
PNAS, December 22, 1998; 95(26): 15730 - 15734.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
W. Danysz and C. G. Parsons
Glycine and N-Methyl-D-Aspartate Receptors: Physiological Significance and Possible Therapeutic Applications
Pharmacol. Rev., December 1, 1998; 50(4): 597 - 664.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
J.F.W. Deakin, M.D.C. Simpson, P. Slater, and J.S.E. Hellewell
Familial and developmental abnormalities of frontal lobe function and neurochemistry in schizophrenia
J Psychopharmacol, January 1, 1997; 11(2): 133 - 142.
[Abstract] [PDF]


Get information about faster international access.

Privacy Policy

Copyright © 1994 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org